Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
Identifieur interne : 000D92 ( Main/Exploration ); précédent : 000D91; suivant : 000D93Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
Auteurs : Colum Downey [Irlande (pays)]Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2016-06.
Abstract
The purpose of this review is to establish whether there is a significantly increased incidence of serious infections during treatment for rheumatoid arthritis (RA) with etanercept, infliximab or adalimumab, to determine the background risk of serious infection in RA patients without treatment with any biological therapy and to ascertain which organisms are involved in serious infections in RA patients while being treated with etanercept, infliximab or adalimumab. Randomised controlled trials (RCTs), meta‐analyses of RCTs, Cochrane reviews, national registry articles and case reports were identified using PubMed/MEDLINE, The Cochrane Library and Google Scholar. The medical subject heading “rheumatoid arthritis” was combined with “serious infection” or “infection” or “adverse drug events” with each of the three reference biological therapies separately: etanercept, infliximab and adalimumab. These electronic searches were limited to human studies, adult studies, those published in the last 10 years (2004–14) and in the English language. Studies which involved the tumor necrosis factor‐α inhibitors certolizumab pegol or golimumab were excluded. The background risk of serious infection appears to be approximately two‐fold more than non‐RA patients before any treatment with biological therapy. The national registries, which may represent the typical RA patient more accurately than clinical trials, suggest a small but significantly increased incidence of serious infection ranging 1.2–2.78 times that of control (treatment with methotrexate). Mycobacteria spp., Staphyloccus aureus, Listeria monocytogenes, Varicella zoster virus and Leishmania species (spp.) repeatedly appear in the case report literature and should be in the mind of the clinician faced with a serious infection in a RA patient with an unknown pathogen who is being treated with either etanercept, infliximab or adalimumab.
Url:
DOI: 10.1111/1756-185X.12659
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002B15
- to stream Istex, to step Curation: 002B15
- to stream Istex, to step Checkpoint: 000011
- to stream Main, to step Merge: 000D93
- to stream Main, to step Curation: 000D92
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review</title><author><name sortKey="Downey, Colum" sort="Downey, Colum" uniqKey="Downey C" first="Colum" last="Downey">Colum Downey</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:260692EE072F24070B6274AED9C37DC9E6D76005</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/1756-185X.12659</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-8VTHFVWX-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002B15</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002B15</idno><idno type="wicri:Area/Istex/Curation">002B15</idno><idno type="wicri:Area/Istex/Checkpoint">000011</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000011</idno><idno type="wicri:doubleKey">1756-1841:2016:Downey C:serious:infection:during</idno><idno type="wicri:Area/Main/Merge">000D93</idno><idno type="wicri:Area/Main/Curation">000D92</idno><idno type="wicri:Area/Main/Exploration">000D92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review</title><author><name sortKey="Downey, Colum" sort="Downey, Colum" uniqKey="Downey C" first="Colum" last="Downey">Colum Downey</name><affiliation wicri:level="4"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Graduate Entry Medical School, University of Limerick, Limerick</wicri:regionArea><orgName type="university">Université de Limerick</orgName><placeName><settlement type="city">Limerick (Irlande)</settlement><region type="région" nuts="2">Munster (Irlande)</region></placeName></affiliation><affiliation wicri:level="4"><orgName type="university">Université de Limerick</orgName><country>Irlande (pays)</country><placeName><settlement type="city">Limerick (Irlande)</settlement><region type="région" nuts="2">Munster (Irlande)</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="536">536</biblScope><biblScope unit="page" to="550">550</biblScope><biblScope unit="page-count">15</biblScope><date type="published" when="2016-06">2016-06</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">The purpose of this review is to establish whether there is a significantly increased incidence of serious infections during treatment for rheumatoid arthritis (RA) with etanercept, infliximab or adalimumab, to determine the background risk of serious infection in RA patients without treatment with any biological therapy and to ascertain which organisms are involved in serious infections in RA patients while being treated with etanercept, infliximab or adalimumab. Randomised controlled trials (RCTs), meta‐analyses of RCTs, Cochrane reviews, national registry articles and case reports were identified using PubMed/MEDLINE, The Cochrane Library and Google Scholar. The medical subject heading “rheumatoid arthritis” was combined with “serious infection” or “infection” or “adverse drug events” with each of the three reference biological therapies separately: etanercept, infliximab and adalimumab. These electronic searches were limited to human studies, adult studies, those published in the last 10 years (2004–14) and in the English language. Studies which involved the tumor necrosis factor‐α inhibitors certolizumab pegol or golimumab were excluded. The background risk of serious infection appears to be approximately two‐fold more than non‐RA patients before any treatment with biological therapy. The national registries, which may represent the typical RA patient more accurately than clinical trials, suggest a small but significantly increased incidence of serious infection ranging 1.2–2.78 times that of control (treatment with methotrexate). Mycobacteria spp., Staphyloccus aureus, Listeria monocytogenes, Varicella zoster virus and Leishmania species (spp.) repeatedly appear in the case report literature and should be in the mind of the clinician faced with a serious infection in a RA patient with an unknown pathogen who is being treated with either etanercept, infliximab or adalimumab.</div></front></TEI><affiliations><list><country><li>Irlande (pays)</li></country><region><li>Munster (Irlande)</li></region><settlement><li>Limerick (Irlande)</li></settlement><orgName><li>Université de Limerick</li></orgName></list><tree><country name="Irlande (pays)"><region name="Munster (Irlande)"><name sortKey="Downey, Colum" sort="Downey, Colum" uniqKey="Downey C" first="Colum" last="Downey">Colum Downey</name></region><name sortKey="Downey, Colum" sort="Downey, Colum" uniqKey="Downey C" first="Colum" last="Downey">Colum Downey</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:260692EE072F24070B6274AED9C37DC9E6D76005
|texte= Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
}}
| This area was generated with Dilib version V0.6.33. |  |